$270 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 64 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ILMN | ILLUMINA INC | $9,241,000 | +18.5% | 25,100 | 0.0% | 3.43% | +18.9% | |
| HALO | Halozyme Therapeutics Inc | $8,162,000 | +6.6% | 475,633 | 0.0% | 3.03% | +7.0% | |
| SAGE | Sage Therapeutics Inc | $6,224,000 | +15.1% | 33,996 | 0.0% | 2.31% | +15.5% | |
| BMRN | Biomarin Pharmaceutical Inc | $5,506,000 | -3.5% | 64,284 | 0.0% | 2.04% | -3.1% | |
| SGEN | Seattle Genetics Inc | $4,215,000 | -5.5% | 60,900 | 0.0% | 1.56% | -5.2% | |
| ABMD | Abiomed Inc | $3,047,000 | -8.8% | 11,700 | 0.0% | 1.13% | -8.4% | |
| AMRN | Amarin Corp Plcsponsored adr | $2,655,000 | -6.5% | 137,000 | 0.0% | 0.98% | -6.3% | |
| ALNY | Alnylam Pharmaceuticals Inc | $2,453,000 | -22.4% | 33,800 | 0.0% | 0.91% | -22.0% | |
| XENT | Intersect Ent Inc | $2,181,000 | -29.3% | 96,000 | 0.0% | 0.81% | -29.0% | |
| BLUE | Bluebird Bio Inc | $2,163,000 | -19.1% | 17,000 | 0.0% | 0.80% | -18.8% | |
| NKTR | NEKTAR THERAPEUTICS | $2,135,000 | +5.9% | 60,000 | 0.0% | 0.79% | +6.3% | |
| AGIO | Agios Pharmaceuticals Inc | $1,821,000 | -26.0% | 36,500 | 0.0% | 0.68% | -25.8% | |
| MYOK | Myokardia INC | $1,505,000 | -3.5% | 30,000 | 0.0% | 0.56% | -3.1% | |
| GBT | Global Blood Therapeutics | $1,472,000 | -0.6% | 28,000 | 0.0% | 0.55% | -0.2% | |
| XLRN | ACCELERON PHARMA INC | $1,233,000 | -11.7% | 30,000 | 0.0% | 0.46% | -11.4% | |
| GMED | Globus Med Inc | $1,024,000 | -14.4% | 24,200 | 0.0% | 0.38% | -14.0% | |
| ARNA | Arena Pharmaceuticals Inc | $967,000 | +30.7% | 16,500 | 0.0% | 0.36% | +31.5% | |
| FGEN | FibroGen Inc | $889,000 | -17.0% | 19,700 | 0.0% | 0.33% | -16.7% | |
| LGND | Ligand Pharmaceuticals Inc | $833,000 | -9.3% | 7,300 | 0.0% | 0.31% | -8.8% | |
| FOLD | Amicus Therapeutics Inc | $730,000 | -8.3% | 58,600 | 0.0% | 0.27% | -7.8% | |
| DERM | Dermira Inc | $287,000 | -29.5% | 30,000 | 0.0% | 0.11% | -29.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.